Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD80 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD80 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CD80 Products |
| Gene Delivery | CD80 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Sequence Verified. |
View CD80 Products |
| Benchmark Ab | Anti-CD80 (Sequence of Galiximab / Abatacept) Recombinant positive control. Sequence Verified. |
View CD80 Products |
| Validator | CD80 siRNA Set For knockdown verification. |
View CD80 Products |
| Related Target A | CD28 Primary co-stimulatory receptor for CD80/CD86, essential for T-cell activation assays. |
View CD28 Products |
| Related Target B | CTLA4 High-affinity co-inhibitory receptor competing with CD28 for CD80 binding. |
View CTLA4 Products |
| Related Target C | CD86 Functional homolog of CD80 with distinct binding kinetics to CD28 and CTLA-4. |
View CD86 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dual Receptor Affinity Profiling (CD28 vs. CTLA-4) | HEK293-expressed CD80, CD28, and CTLA-4 proteins with native glycosylation for precise SPR/BLI kinetics. |
| Cross-Species Reactivity Screen | Human, Cynomolgus, and Mouse CD80 ortholog proteins strictly verified by Mass Spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD80 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD80 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies, fusion proteins, and engineered APC-like modalities. As first-generation therapies (such as CTLA-4-Ig) reach maturity in autoimmune indications, the next wave of R&D is targeting CD80-mediated co-stimulation in oncology, specifically leveraging CD80-Fc fusion variants and CD80 x PD-L1 bispecifics to selectively activate T-cells within the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Fusion Protein (CTLA-4-Ig) | Bristol Myers Squibb, Alpine Immune Sciences | Rheumatoid Arthritis, Transplant Rejection | Receptor Blocking Assay (Need high-purity CD80 and CD86 ECD-Fc) |
| Bispecific / Bifunctional | AstraZeneca, Harbour BioMed | Solid Tumors, Autoimmune Diseases | Dual-targeting Validation (Need cross-reactive CD80 and PD-L1 proteins) |
| Monoclonal Antibody | Biogen (Galiximab) | B-cell Lymphoma, Autoimmune | Epitope Mapping & Affinity Screen (Need Sequence-verified CD80 mutants) |